Xbrane Biopharma has filed three patent applications covering novel nucleic acid sequences encoding various signal peptides that have been demonstrated to have significant impact on yield and thereby production cost of recombinant proteins.
“We are an innovative company continuously strengthening our platform technology with the focus of having the lowest production cost in the industry of the biosimilars we chose to do. Going forward we will put more emphasis on building an IP-portfolio around our platform technology to better protect and monetize on our research. The recently filed patents cover new inventions that further strengthen our platform,” says Martin Åmark, CEO Xbrane.
Lowering the production cost of recombinant proteins
The company has recently filed the three patent applications to the Swedish patent and Registration Office (PRV).
The patent applications relate to novel methods of using signal peptides to enhance the production yield and thereby lowering the production cost of recombinant proteins. Recombinant proteins are produced via the introduction of a DNA-sequence into a living cell instructing it to produce the protein of interest, often the intended active ingredient in a pharmaceutical product. Signal peptides typically function to prompt a cell to translocate the recombinant protein, usually through and across the cellular membrane.
It has been demonstrated in the recently filed patent applications that certain nucleic acid sequences of the DNA sequences encoding the signal peptides positively impact the production yield, i.e. the amount of the targeted recombinant protein produced at a given scale of fermentation. The recently filed patent applications relate to specific such novel nucleic acid sequences encoding various signal peptides that have been demonstrated to have significant impact on production yield.
Follow-up with international patent applications
The ambition is to follow-up the patent applications with international patent applications with focus on commercially important jurisdictions such as USA, Europe, Japan and China.
The recently filed patent applications are jointly owned, at equal shares, by Xbrane and CloneOpt, a Stockholm University spin-out. The patent applications are part of several planned patent applications which the newly established IP department of Xbrane will file either alone or jointly with other companies to build a broader IP portfolio around Xbrane’s platform technology.
Photo of Martin Åmark, CEO, Xbrane Biopharma